Company intelligence / Profile preview
Sciwind Biosciences
Hangzhou, Zhejiang, Chinaprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Sciwind Biosciences has successfully completed Phase III clinical trials for its long-acting GLP-1 analog, ecnoglutide (XW003), and is developing oral formulations like XW004 and small molecule GLP-1RAs like XW014.
- Therapeutic areas
- GastroenterologyEndocrinology
- Modalities
- Peptide analogssmall molecules
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
Verdiva Bio (global licensing agreement)
Beyond the preview
Go deeper on Sciwind Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sciwind Biosciences.